Clinical Trial Update: A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 gene therapy trial for Homozygous Familial Hypercholesterolemia (HoFH) has been terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Snippet

Sponsor: REGENXBIO Inc. | Conditions: Homozygous Familial Hypercholesterolemia (HoFH) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-07-13